Dexcom announces pediatric clearance for Stelo and app launch
The company also plans international expansion in UK, Australia, New Zealand, and South Korea.
See the latest news and media coverage for Dexcom. We track all announcements, press releases, and industry mentions in real time, all in one place.
Manufacturer of continuous glucose monitoring systems
dexcom.comLast updated
In short: Dexcom reported 15% revenue growth in Q1 2026, launched the next-generation G8 CGM, and expanded its portfolio through the acquisition of Nutrisense.
The company also plans international expansion in UK, Australia, New Zealand, and South Korea.
New CONNECT trial results, Stelo app redesign, and Nutrisense acquisition support earlier intervention and preventative care.
Revenue grows 15% to $1.192 billion. Operating income rises to $255.3 million. Raises 2026 guidance. Expands Dexcom G7 launch.
Registry data shows G7 aids weight management and A1C reduction in non-insulin patients. Symposium shares upcoming features and CGM competency framework.
Insulet Corporation (PODD) and DexCom (DXCM) were among notable gainers in MedTech on Tuesday after Deutsche Bank initiated the diabetes device makers with Buy ratings...
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it...
BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on June 15 and set a price target of $80.00. The company's shares closed yesterday...
DexCom, Inc. (NASDAQ:DXCM) is one of the 12 High Quality Stocks to Buy for the Long Term. On June 15...
Track Dexcom and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Dexcom and other trending companies.